GeneGo is Awarded Phase II NCI Grant for Network Biomarkers in Breast Cancer
Complete the form below to unlock access to ALL audio articles.
GeneGo, Inc. has announced that they have been awarded a Phase II SBIR grant from the National Cancer Institute for discovery of biomarkers implicated in breast cancer based on network analysis.
The research program includes a large scale gene expression and genotyping study to be run at Mayo Clinic and data analysis in MetaCore™.
"We are very happy to receive this Phase II award from NCI in the current highly competitive environment as it validates our commitment to scientific research and our novel, innovative ideas in pathway analysis," said Dr. Tatiana Nikolskaya, Chief Scientific Officer and President of GeneGo.
"In Phase I, we made some exciting new findings in sub-categorization of breast cancers based on network analysis of previously published microarray expression data."
"However, the biomarkers found in such 'meta-analysis' have to be validated in a new design study in a stringent clinical environment."
"We are pleased to collaborate with Mayo Clinic, a world leading institution in clinical and research oncology."
"The microarray and genotyping assays will be conducted at Mayo labs, and the analysis will be performed with state-of-the-art translational medicine and systems biology tools."
